---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003405"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T09:35:38.421685+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal

## Summary
- Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.
- Phase 2 Tailwind study of inhaled AP-PA02 in NCFB showed statistically significant reduction of P.a. CFUs; well-tolerated.
- Phase 1b/2a diSArm study of IV AP-SA02 for S. aureus bacteremia enrollment complete; topline data expected H1 2025.
- Entered $10M secured credit agreement with Innoviva subsidiary at 14% interest, maturing March 2026; existing loans also extended.

## SEC filing metadata
- accession: 0001558370-25-003405
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/0001558370-25-003405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837025003405/armp-20250320x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003405
- JSON: https://secwatch.observer/filing/0001558370-25-003405.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.